AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) announced preliminary results of a rights offering that expired March 3, 2026, estimating aggregate subscriptions of approximately $1.8 million.

The offering sold Units at $1,000 per Unit (one Series G convertible preferred share plus 2,000 Class G warrants). Closing is anticipated on or about March 6, 2026, subject to customary conditions.

News Market Reaction – AIM

-1.31%

3 alerts

-1.31% Session close to close

-17.0% Trough Tracked

$2.42M Market Cap

0.1x Rel. Volume

In the Mar 4 session, AIM declined 1.31%, reflecting a mild negative market reaction. Argus tracked a trough of -17.0% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement reports preliminary results of AIM’s rights offering, with estimated gross proceed...

Analysis

This announcement reports preliminary results of AIM’s rights offering, with estimated gross proceeds of about $1.8 million from Units priced at $1,000 that bundle Series G convertible preferred stock and 2,000 warrants each. It follows a series of prior offering-related filings targeting up to $12.0 million and sits alongside a broader $100 million shelf registration. Investors may watch final subscription figures, additional shelf takedowns, and how this funding supports ongoing Ampligen development.

Key Figures

Rights offering proceeds: $1.8 million Unit subscription price: $1,000 per Unit Warrants per Unit: 2,000 warrants +5 more

8 metrics

Rights offering proceeds $1.8 million Estimated aggregate gross proceeds from current rights offering

Unit subscription price $1,000 per Unit Price per Unit in current rights offering

Warrants per Unit 2,000 warrants Class G Common Stock Purchase Warrants per Unit in current offering

Units offered 12,000 Units Maximum Units in registered rights offering

Max gross proceeds $12.0 million Targeted gross proceeds if rights offering fully subscribed

Warrant shares 24,000,000 shares Maximum common shares underlying Warrants in rights offering

Conversion shares 12,000,000 shares Common shares issuable upon Series G preferred conversion

Shelf capacity $100 million Aggregate amount under Form S-3/A shelf registration

Previous Offering Reports

5 past events · Latest: Feb 25 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 25	Rights offering extension	Negative	-4.7%	Extended subscription period for existing rights offering to March 3, 2026.
Feb 12	Rights offering terms	Negative	+58.2%	Corrected commencement terms for rights offering targeting $12.0M gross proceeds.
Feb 11	Offering launch	Negative	-13.5%	Launched rights offering of up to 12,000 Units at $1,000 per Unit.
Jan 27	Offering term change	Negative	+0.8%	Revised dates and terms for planned rights offering and use of proceeds.
Jan 23	Planned rights offering	Negative	-5.2%	Announced proposed rights offering expected to raise up to $12.0M.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Offering-related headlines often skew negative for AIM, though there have been a few sharp upside surprises around earlier rights-offering steps.

Recent Company History

Over recent months AIM has issued a series of rights offering updates, from initial key terms on Jan 23, 2026 through multiple amendments and extensions targeting up to $12.0 million via 12,000 Units. Market reactions have been mixed: some offering announcements saw double-digit declines, while the Feb 12, 2026 correction headline produced a strong gain. Today’s preliminary result of about $1.8 million fits into this ongoing capital-raising effort for Ampligen and related programs.

Key Terms

rights offering, convertible preferred stock, common stock purchase warrants, registration statement on Form S-1, +1 more

5 terms

rights offering financial

"today announced the preliminary results of its previously announced rights offering"

A rights offering is a way for a company to raise additional money by giving existing shareholders the opportunity to buy more shares at a discounted price before they are offered to the public. It’s similar to a special sale where current owners get the first chance to buy extra items at a lower cost, allowing them to increase their investment if they choose. This process matters to investors because it can affect the value of their holdings and their ability to buy new shares at favorable terms.

View in glossary

convertible preferred stock financial

"consisting of one share of the Company’s Series G Convertible Preferred Stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

common stock purchase warrants financial

"and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock"

Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.

registration statement on Form S-1 regulatory

"The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The prospectus relating to and describing the terms of the Rights Offering has been filed"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced the preliminary results of its previously announced rights offering (the “Rights Offering”) which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8 million. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer Solutions, LLC.

Each right entitled the holder to purchase one unit (“Unit”), at a subscription price of $1,000 per Unit, consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock (the “Warrants”).

The Company anticipates the closing of the Rights Offering will occur on or about March 6, 2026, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of the Preferred Stock and Warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.

Maxim Group LLC acted as dealer-manager for the Rights Offering. Questions about the Rights Offering or requests for copies of the final prospectus may be directed to Maxim Group LLC at 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (“SEC”) on February 10, 2026. The prospectus relating to and describing the terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC's website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

Forward Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

IR Contact:

JTC Team, LLC

Jenene Thomas

908.824.0775

AIM@jtcir.com

FAQ

How much did AIM raise in the March 2026 rights offering (AIM)?

Approximately $1.8 million in aggregate subscriptions, according to the company. This figure is preliminary and subject to final verification by AIM and its subscription agent prior to closing.

What does each Unit include in AIM's rights offering (AIM)?

Each Unit is priced at $1,000 and includes one Series G convertible preferred share plus 2,000 Class G common stock purchase warrants, according to the company. No physical certificates will be issued; holdings will be book-entry.

When is AIM expecting the closing of the rights offering (AIM)?

AIM anticipates closing on or about March 6, 2026, subject to satisfaction or waiver of conditions, according to the company. Finalization and verification by the subscription agent could affect timing.

How will AIM distribute shares and warrants to exercising rights holders (AIM)?

Shares and warrants will be distributed by direct registration in book-entry form or via DTC, according to the company. Holders who validly exercised and paid will receive electronic credit; no physical certificates will be issued.

Who managed AIM's rights offering and how can investors get the prospectus (AIM)?

Maxim Group acted as dealer-manager; the prospectus was filed with the SEC, according to the company. Investors can request the final prospectus from Maxim or access it on the SEC website.

Are AIM's rights offering results final and where are they filed (AIM)?

The results are preliminary and subject to change pending final verification by AIM and Broadridge, according to the company. The offering is described in a registration statement declared effective by the SEC on February 10, 2026.